Prospects for Bayer’s oral Factor XIa inhibitor asundexian have improved markedly after a phase 3 trial in secondary stroke prevention.
Otsuka preps for July decision on centanafadine for ADHD
The FDA has started a priority review of Otsuka’s triple-acting drug for ADHD, setting up a decision on the first-in-class drug in July.


